Guardant Health's Shield Blood Test for Colorectal Cancer Screening Gets FDA Approval
Portfolio Pulse from Benzinga Newsdesk
Guardant Health's Shield blood test for colorectal cancer screening has received FDA approval, making it the first blood test approved as a primary screening option for CRC. This approval also meets Medicare coverage requirements, potentially increasing CRC screening rates in the U.S.
July 29, 2024 | 10:31 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Guardant Health's Shield blood test for colorectal cancer screening has received FDA approval, making it the first blood test approved as a primary screening option for CRC. This approval also meets Medicare coverage requirements, potentially increasing CRC screening rates in the U.S.
The FDA approval of Guardant Health's Shield blood test as a primary screening option for colorectal cancer is a significant milestone. This approval not only validates the efficacy of the test but also opens up a large market of individuals who are currently not up to date with their CRC screening. The Medicare coverage further enhances the accessibility and adoption of the test, likely leading to increased revenues for Guardant Health.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100